- Home
- RMM vs STRO Comparison
RMM vs STRO Comparison
Compare RMM & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- STRO
- Stock Information
- Founded
- RMM 2019
- STRO 2003
- Country
- RMM United States
- STRO United States
- Employees
- RMM N/A
- STRO N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMM Finance
- STRO Health Care
- Exchange
- RMM Nasdaq
- STRO Nasdaq
- Market Cap
- RMM 303.8M
- STRO 292.6M
- IPO Year
- RMM N/A
- STRO 2018
- Fundamental
- Price
- RMM $15.92
- STRO $2.84
- Analyst Decision
- RMM
- STRO Strong Buy
- Analyst Count
- RMM 0
- STRO 7
- Target Price
- RMM N/A
- STRO $12.14
- AVG Volume (30 Days)
- RMM 66.5K
- STRO 921.2K
- Earning Date
- RMM 01-01-0001
- STRO 11-13-2024
- Dividend Yield
- RMM 7.33%
- STRO N/A
- EPS Growth
- RMM N/A
- STRO N/A
- EPS
- RMM 0.96
- STRO N/A
- Revenue
- RMM N/A
- STRO $160,955,000.00
- Revenue This Year
- RMM N/A
- STRO N/A
- Revenue Next Year
- RMM N/A
- STRO N/A
- P/E Ratio
- RMM $15.55
- STRO N/A
- Revenue Growth
- RMM N/A
- STRO 230.90
- 52 Week Low
- RMM $12.32
- STRO $2.45
- 52 Week High
- RMM $16.10
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- RMM 62.09
- STRO 40.85
- Support Level
- RMM $15.48
- STRO $2.66
- Resistance Level
- RMM $15.92
- STRO $2.86
- Average True Range (ATR)
- RMM 0.17
- STRO 0.25
- MACD
- RMM 0.06
- STRO -0.01
- Stochastic Oscillator
- RMM 100.00
- STRO 24.22
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.